Current stage-Stage III (Advanced) Posts on Medivizor
Navigation Menu

Current stage-Stage III (Advanced) Posts on Medivizor

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Posted by on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...

Read More

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Posted by on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with...

Read More

Evaluating the effectiveness of brentuximab vedotin and AVD chemotherapy combination in high-risk patients with advanced classical Hodgkin lymphoma

Evaluating the effectiveness of brentuximab vedotin and AVD chemotherapy combination in high-risk patients with advanced classical Hodgkin lymphoma

Posted by on Feb 21, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the long-term safety and effectiveness of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and brentuximab vedotin (Adcedris; A) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations in high-risk patients with advanced classical Hodgkin lymphoma (cHL). The data showed that the A+AVD...

Read More

How effective is rituximab, bendamustine, mitoxantrone (R-BM) and rituximab consolidation as a treatment regimen for elderly patients with advanced follicular lymphoma?

How effective is rituximab, bendamustine, mitoxantrone (R-BM) and rituximab consolidation as a treatment regimen for elderly patients with advanced follicular lymphoma?

Posted by on Feb 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate if rituximab (Rituxan), bendamustine (Treanda), and mitoxantrone (Novantrone) or R-BM followed by rituximab consolidation was a safe and effective treatment in older patients with follicular lymphoma (FL). The authors concluded that this treatment provided durable responses and was well tolerated in...

Read More

Can lenalidomide maintenance improve survival after autologous hematopoietic stem-cell transplantation in patients with mantle cell lymphoma?

Can lenalidomide maintenance improve survival after autologous hematopoietic stem-cell transplantation in patients with mantle cell lymphoma?

Posted by on Feb 6, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated whether lenalidomide maintenance therapy after intensive chemoimmunotherapy and first-line autologous hematopoietic stem-cell transplantation (AHSCT) improved the outcomes of patients with mantle cell lymphoma (MCL). The data showed that lenalidomide maintenance after AHSCT improved the survival without...

Read More

Avoiding consolidation radiotherapy in advanced Hodgkin lymphoma with large nodes after ABVD chemotherapy

Avoiding consolidation radiotherapy in advanced Hodgkin lymphoma with large nodes after ABVD chemotherapy

Posted by on Sep 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the impact of consolidation radiotherapy (cRT) on patients with advanced Hodgkin lymphoma (HL) who had large nodal mass (LNM) and currently in complete metabolic response (CMR) after receiving ABVD chemotherapy. The authors found that cRT could be safely avoided in such patients. Some background CMR defines...

Read More

The impact of G-CSF on brentuximab vedotin plus chemotherapy in treating newly diagnosed advanced Hodgkin lymphoma

The impact of G-CSF on brentuximab vedotin plus chemotherapy in treating newly diagnosed advanced Hodgkin lymphoma

Posted by on Sep 20, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the impact of granulocyte-colony stimulating factor (G-CSF; Neupogen) on the outcomes of brentuximab-vedotin (BV; Adcetris) plus chemotherapy in newly diagnosed patients with stage-III/IV Hodgkin lymphoma (HL). The authors found that G-CSF improved the safety and efficacy outcomes of the combination therapy in such...

Read More

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Posted by on Sep 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...

Read More

Looking for patients with follicular lymphoma to trial an experimental treatment.

Looking for patients with follicular lymphoma to trial an experimental treatment.

Posted by on Aug 30, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial is looking to assess the effectiveness of ME-401 for relapsed follicular lymphoma (FL) after the failure of two or more therapies. The main outcome to be measured in this trial is the percentage of patients whose cancer shrinks or disappears after treatment.  The details FL is a type of non-Hodgkin lymphoma....

Read More

Evaluating lenalidomide-rituximab treatment for follicular lymphoma

Evaluating lenalidomide-rituximab treatment for follicular lymphoma

Posted by on Aug 23, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effectiveness of rituxumab (Rituxan) with lenalidomide (Revlimid) for untreated follicular lymphoma (FL). It found that this treatment was more effective than rituxumab with chemotherapy. They also found that blood tests of trace FL can predict outcomes. Some background Follicular lymphoma (FL) is a slow-growing...

Read More

Long-term outcomes of brentuximab vedotin with chemotherapy for patients with advanced classical Hodgkin lymphoma

Long-term outcomes of brentuximab vedotin with chemotherapy for patients with advanced classical Hodgkin lymphoma

Posted by on May 17, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and brentuximab vedotin (Adcedris; A) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations to understand which is more effective long term for patients with advanced classical Hodgkin lymphoma (HL). The authors concluded...

Read More

Searching for patients to try a new therapy for advanced solid tumors.

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...

Read More